Magnetic nanoparticles and their applications in image-guided drug delivery

Drug Delivery and Translational Research

Volumn 2, Issue 1, 2012, Pages 3-21

  Yu, Mi Kyung ^a   Park, Jinho ^a   Jon, Sangyong ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

Hyperthermia; Image guided drug delivery; Magnetic drug targeting; Magnetic nanoparticles; Multifunctional nanoparticles; Theranostics

Indexed keywords

ANTIBODY; APTAMER; EPIRUBICIN; FERUMOXSIL; GADOLINIUM PENTETATE; LIPOSOME; LUMIREN; MAGNETIC NANOPARTICLE; MITOXANTRONE; PEPTIDE DERIVATIVE; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; DRUG DELIVERY SYSTEM; HUMAN; HYPERTHERMIA; IMAGING SYSTEM; NANOPHARMACEUTICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW;

EID: 84865526610     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-011-0049-8     Document Type: Review

References (91)

1. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001;11:2319-31.
2. Bonnemain B. Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. J Drug Target. 1998;6:167-74.
3. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491-9.
4. Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012;2:3-44.
5. Erathodiyil N, Ying JY. Functionalization of inorganic nanoparticles for bioimaging applications. Acc Chem Res. 2011;44:925-35.
6. Yang J, Wadghiri YZ, Hoang DM, Tsui W, Sun Y, Chung E, et al. Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. NeuroImage. 2011;55:1600-9.
7. Lim SW, Kim HW, Jun HY, Park SH, Yoon KH, Kim HS, et al. TCLSPION- enhanced MRI for the detection of lymph node metastasis in murine experimental model. Acad Radiol. 2011;18:504-11.
8. Tan M, Lu ZR. Integrin targeted MR imaging. Theranostics 2011;1:83-101.
9. Daldrup-Link HE, Golovko D, Ruffel B, Denardo D, Castaneda R, Ansari C, et al. MR imaging of tumor associated macrophages with clinically-applicable iron oxide nanoparticles. Clin Cancer Res. 2011;17:5695-704.
10. Mahmoudi M, Hosseinkhani H, Hosseinkhani M, Boutry S, Simchi A, Journeay WS, et al. Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerativemedicine. Chem Rev. 2011;111:253-80.
11. Solanki A, Kim JD, Lee KB. Nanotechnology for regenerative medicine: nanomaterials for stem cell imaging. Nanomedicine. 2008;3:567-78.
12. Yang X, Grailer JJ, Rowland IJ, Javadi A, Hurley SA, Matson VZ, et al. Multifunctional stable and pH-responsive polymer vesicles formed by heterofunctional triblock copolymer for targeted anticancer drug delivery and ultrasensitive MR imaging. ACS Nano. 2010;4:6805-17.
13. Chen GJ, Wang LF. Design of magnetic nanoparticles-assisted drug delivery system. Curr Pharm Des. 2011;17:2331-51.
14. Ho D, Sun X, Sun S. Monodisperse magnetic nanoparticles for theranostic applications. Acc Chem Res. 2011;44:875-82.
15. Cheon J, Lee JH. Synergistically integrated nanoparticles as multimodal probes for nanobiotechnology. Acc Chem Res. 2008;41:1630-40.
16. Jun YW, Lee JH, Cheon J. Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. Angew Chem Int Ed Engl. 2008;47:5122-35.
17. Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008;60:1252-65.
18. Tandon P, Farahani K. NCI image-guided drug delivery summit. Cancer Res. 2011;71:314-7.
19. Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng. 2006;34:23-38.
20. Jun YW, Huh YM, Choi JS, Lee JH, Song HT, Kim S, et al. Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J Am Chem Soc. 2005;127:5732-3.
21. Lee JH, Huh YM, Jun YW, Seo JW, Jang JT, Song HT, et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med. 2007;13:95-9.
22. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263:1600-3.
23. Berry CC, Curtis ASG. Functionalisation of magnetic nanoparticles for applications in biomedicine. J Phys D: Appl Phys. 2003;36: R198-206.
24. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53:283-318.
25. Xie J, Xu C, Kohler N, Hou Y, Sun S. Controlled PEGylation of monodisperse Fe3O4 nanoparticles for reduced non-specific uptake by macrophage cells. Adv Mater. 2007;19:3163-6.
26. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, et al. Superparamagnetic iron oxide-pharmacokinetic and toxicity. AJR Am J Roentgenol. 1989;152:167-73.
27. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide-an intravenous contrast agent for assessing lymph-nodes with MR imaging. Radiology. 1990;175:494-8.
28. Stark DD, Weissleder R, Elizondo G, Hahn PF, Saini S, Todd LE, et al. Superparamagnetic iron oxide-clinical application as a contrast agent for MR imaging of the liver. Radiology. 1988;168:297-301.
29. Chastellain M, Petri A, Hofmann H. Superparamagnetic iron oxide nanoparticles for biomedical applications: a focus on PVA as a coating. Quantum Dots, Nanoparticles and Nanowires. 2004;789:269-72.
30. Liu HL, Ko SP, Wu JH, Jung MH, Min JH, Lee JH, et al. One-pot polyol synthesis of monosize PVP-coated sub-5 nm Fe3O4 nanoparticles for biomedical applications. J Magn Magn Mater. 2007;310:E815-7.
31. Ma YH, Wu SY, Wu T, Chang YJ, Hua MY, Chen JP. Magnetically targeted thrombolysis with recombinant tissue plasminogen activator bound to polyacrylic acid-coated nanoparticles. Biomaterials. 2009;30:3343-51.
32. Portet D, Denizot B, Rump E, Lejeune JJ, Jallet P. Nonpolymeric coatings of iron oxide colloids for biological use as magnetic resonance imaging contrast agents. J Colloid Interface Sci. 2001;238:37-42.
33. Fauconnier N, Pons JN, Roger J, Bee A. Thiolation of maghemite nanoparticles by dimercaptosuccinic acid. J Colloid Interface Sci. 1997;194:427-33.
34. Zhang C, Wangler B, Morgenstern B, Zentgraf H, Eisenhut M, Untenecker H, et al. Silica- and alkoxysilane-coated ultrasmall superparamagnetic iron oxide particles: a promising tool to label cells for magnetic resonance imaging. Langmuir. 2007;23:1427-34.
35. Zhang Z, Chao T, Chen SF, Jiang SY. Superlow fouling sulfobetaine and carboxybetaine polymers on glass slides. Langmuir. 2006;22:10072-7.
36. Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J. Magnetic nanoparticles for drug delivery. Nano Today. 2007;2:22-32.
37. Vonarbourg A, Passirani C, Saulnier P, Benoit JP. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials. 2006;27:4356-73.
38. Neuberger T, Schöpf B, Hofmann H, Hofmann M, Von Rechenberg B. Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. J Magn Magn Mater. 2005;293:483-96.
39. Reimer P, Jähnke N, Fiebich M, Schima W, Deckers F, Marx C, et al. Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxideenhanced MR imaging, and spiral CT-ROC analysis. Radiology. 2000;217:152-8.
40. Weissleder R, Elizondo G, Stark DD, Hahn PF, Marfil J, Gonzalez JF, et al. The diagnosis of splenic lymphoma by MR imaging: value of superparamagnetic iron oxide. AJR Am J Roentgenol. 1989;152:175-80.
41. Schmitz SA, Coupland SE, Gust R, Winterhalter S, Wagner S, Kresse M, et al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol. 2000;35:460-71.
42. Murillo TP, Sandquist C, Jacobs PM, Nesbit G, Manninger S, Neuwelt EA. Imaging brain tumors with ferumoxtran-10, a nanoparticle magnetic resonance contrast agent. Therapy. 2005;2:871-82.
43. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189-207.
44. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 2009;9:1909-15.
45. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5:496-504.
46. Chouly C, Pouliquen D, Lucet I, Jeune JJ, Jallet P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J Microencapsul. 1996;13:245-55.
47. Park JH, von Maltzahn G, Zhang L, Derfus AM, Simberg D, Harris TJ, et al. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small. 2009;5:694-700.
48. Jordan A, Scholz R, Wust P, Fähling H, Felix R. Magnetic fluid hyperthermia (MFH): cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles. J Magn Magn Mater. 1999;201:413-9.
49. Hergt R, Dutz S, Müller R, Zeisberger M. Magnetic particle hyperthermia: nanoparticle magnetism and materials development for cancer therapy. J Phys Condens Matter. 2006;18: S2919-34.
50. Fortin JP, Wilhelm C, Servais J, Ménager C, Bacri JC, Gazeau F. Size-sorted anionic iron oxide nanomagnets as colloidal mediators for magnetic hyperthermia. J Am Chem Soc. 2007;129:2628-35.
51. Rosensweig RE. Heating magnetic fluid with alternating magnetic field. J Magn Magn Mater. 2002;252:370-4.
52. Lee JH, Jang JT, Choi JS, Moon SH, Noh SH, Kim JW, et al. Exchange-coupled magnetic nanoparticles for efficient heat induction. Nat Nanotechnol. 2011;6:418-22.
53. Derfus AM, von Maltzahn G, Harris TJ, Duza T, Vecchio KS, Ruoslahti E, et al. Remotely triggered release from magnetic nanoparticles. Adv Mater. 2007;19:3932-6.
54. Thomas CR, Ferris DP, Lee JH, Choi E, Cho MH, Kim ES, et al. Noninvasive remote-controlled release of drug molecules in vitro using magnetic actuation of mechanized nanoparticles. J Am Chem Soc. 2010;132:10623-5.
55. Hergt R, Dutz S. Magnetic particle hyperthermia-biophysical limitations of a visionary tumour therapy. J Magn Magn Mater. 2007;311:187-91.
56. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, et al. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst. 2007;99:53-63.
57. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, et al. In vivomonitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med. 2004;51:1153-62.
58. Langereis S, Keupp J, van Velthoven JL, de Roos IH, Burdinski D, Pikkemaat JA, et al. A temperature-sensitive liposomal 1H CEST and 19 F contrast agent for MR image-guided drug delivery. J Am Chem Soc. 2009;131:1380-1.
59. Aime S, Delli Castelli D, Terreno E. Highly sensitive MRI chemicall exchange saturation transfer agents using liposomes. Angew Chem Int Ed Engl. 2005;44:5513-5.
60. de Smet M, Langereis S, van den Bosch S, Grüll H. Temperaturesensitive liposomes for doxorubicin delivery under MRI guidance. J Control Release. 2010;143:120-7.
61. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000;60:6641-8.
62. Lübbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, et al. Clinical experiences withmagnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 1996;56:4686-93.
63. Lübbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res. 1996;56:4694-701.
64. Wilson MW, Kerlan Jr RK, Fidelman NA, Venook AP, LaBerge JM, Koda J, et al. Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/conventional angiography suite-initial experience with four patients. Radiology. 2004;230:287-93.
65. Mikhaylov G, Mikac U, Magaeva AA, Itin VI, Naiden EP, Psakhye I, et al. Ferri-liposomes as an MRI-visible drugdelivery system for targeting tumours and their microenvironment. Nat Nanotechnol. 2011;6:594-602.
66. Naiden EP, Zhuravlev VA, Itin VI, Terekhova OG, Magaeva AA, Ivanov Yu F. Magnetic properties and structural parameters of nanosized oxide ferrimagnet powders produced by mechanochemical synthesis from salt solutions. Phys Solid State. 2003;5:891-900.
67. Liu HL, Hua MY, Yang HW, Huang CY, Chu PC, Wu JS, et al. Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc Natl Acad Sci U S A. 2010;107:15205-10.
68. Hynynen K, McDannold N, Vykhodtseva N, Raymond S, Weissleder R, Jolesz FA, et al. Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neurosurg. 2006;105:445-54.
69. Medarova Z, Pham W, Farrar C, Petkova V, Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med. 2007;13:372-7.
70. Kumar M, Yigit M, Dai G, Moore A, Medarova Z. Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res. 2010;70:7553-61.
71. Chen G, Chen W, Wu Z, Yuan R, Li H, Gao J, et al. MRI-visible polymeric vector bearing CD3 single chain antibody for gene delivery to T cells for immunosuppression. Biomaterials. 2009;30:1962-70.
72. Olenchock BA, Guo R, Carpenter JH, Jordan M, Topham MK, Koretzky GA, et al. Disruption of diacylglycerol metabolism impairs the induction of T cell anergy. Nat Immunol. 2006;7:1174-81.
73. Ling Y, Wei K, Luo Y, Gao X, Zhong S. Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy. Biomaterials. 2011;32:7139-50.
74. Yu MK, Jeong YY, Park J, Park S, Kim JW, Min JJ, et al. Drugloaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew Chem Int Ed Engl. 2008;47:5362-5.
75. Dubertret B, Calame M, Libchaber AJ. Single-mismatch detection using gold-quenched fluorescent oligonucleotides. Nat Biotechnol. 2001;19:365-70.
76. Yu MK, Kim D, Lee IH, So JS, Jeong YY, Jon S. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small. 2011;7:2241-9.
77. Lim EK, Huh YM, Yang J, Lee K, Suh JS, Haam S. pH-triggered drug-releasing magnetic nanoparticles for cancer therapy guided by molecular imaging by MRI. Adv Mater. 2011;23:2436-42.
78. Kaye AH, Morstyn G, Brownbill D. Adjuvant high dose photoradiation therapy in the treatment of cerebral glioma: a phase 1-2 study. J Neurosurg. 1987;67:500-5.
79. Stylli SS, Howes M, MacGregor L, Rajendra P, Kaye AH. Photodynamic therapy of brain tumours: evaluation of porphyrin uptake versus clinical outcome. J Clin Neurosci. 2004;11:584-96.
80. Jeong H, Huh M, Lee SJ, Koo H, Kwon IC, Jeong SY, Kim K. Photosensitizer-conjugated human serum albumin nanoparticles for effective photodynamic therapy. Theranostics. 2011;1:230-9.
81. Reddy GR, Bhojani MS, McConville P, Moody J, Moffat BA, Hall DE, et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res. 2006;12:6677-86.
82. Roth Y, Tichler T, Kostenich G, Ruiz-Cabello J, Maier SE, Cohen JS, et al. High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. Radiology. 2004;232:685-92.
83. Hadjipanayis CG, Machaidze R, Kaluzova M, Wang L, Schuette AJ, Chen H, et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convectionenhanced delivery and targeted therapy of glioblastoma. Cancer Res. 2010;70:6303-12.
84. Raghavan R, Brady ML, Rodríguez-Ponce MI, Hartlep A, Pedain C, Sampson JH. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus. 2006;20:E12.
85. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994;91:2076-80.
86. Hadjipanayis CG, Fellows-Mayle W, Deluca NA. Therapeutic efficacy of a herpes simplex virus in combination with radiation or temozolomide for intracranial glioblastoma after convectionenhanced delivery. Mol Ther. 2008;16:1783-8.
87. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev. 2007;220:129-50.
88. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity. 2008;29:372-83.
89. Bae MY, Cho NH, Seong SY. Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli. Clin Exp Immunol. 2009;157:128-38.
90. Chang E, Thekkek N, Yu WW, Colvin VL, Drezek R. Evaluation of quantum dot cytotoxicity based on intracellular uptake. Small. 2006;2:1412-7.
91. Cho NH, Cheong TC, Min JH, Wu JH, Lee SJ, Kim D, et al. A multifunctional core-shell nanoparticle for dendritic cellbased cancer immunotherapy. Nat Nanotechnol. 2011;6:675-82.